FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

1,063 letters match. Newest first.

  1. Diamond-Herpanacine of PA, Inc.

    FDA says Diamond-Herpanacine supplement claims make its eye and skin products unapproved drugs.

    Low
  2. Naumes, Inc.

    FDA warned Naumes, Inc. that its pears may have been contaminated with filth after an inspection found produce-safety violations.

    High risk
  3. Supersmart USA, LLC

    FDA says Supersmart USA sold dietary supplements with disease-treatment claims, making them unapproved and misbranded drugs.

    Low
  4. Min Jiang Food Store Inc dba Koi Koi Trading

    FDA found Listeria on food-contact surfaces at Koi Koi Trading's ready-to-eat seafood plant and cites seafood HACCP failures.

    High risk
  5. RSV Pita, Inc. DBA Pita Pan Bakery

    FDA warns Pita Pan Bakery that ready-to-eat pita, bagels and challah were made under insanitary conditions and had undeclared allergens.

    High risk
  6. Foshan Miwei Cosmetics Co., Ltd.

    FDA warns Foshan Miwei Cosmetics over manufacturing practice failures and unapproved, misbranded over-the-counter (OTC) sunscreen drugs; drugs on import alert.

    High risk
  7. The Wilatta Group Inc.

    FDA warns The Wilatta Group Inc. that it imported foods without required foreign supplier verification programs.

    Medium
  8. Nupack Inc.

    FDA warned Nupack Inc. that its dietary supplements were unapproved drugs and made without required manufacturing-practice records.

    High risk
  9. SaNOtize

    FDA warns SaNOtize that NOWONDER Nasal Cleanser is an unapproved new drug sold in the U.S. with antiviral claims.

    Medium
  10. Par Health USA, LLC & Endo USA, Inc.

    FDA cited Par Health USA/Endo USA’s Rochester plant for sterile injectable contamination-control, media fill, and visual inspection failures after an October 2025 inspection.

    High risk
  11. UCSF Radiopharmaceutical Facility

    FDA cited UCSF Radiopharmaceutical Facility for inadequate sterility failure investigations and environmental monitoring of sterile drug manufacturing.

    High risk
  12. Xiamen Kang Zhongyuan Biotechnology Co., Ltd.

    FDA found filthy conditions and falsified records at Chinese drug maker Xiamen Kang Zhongyuan; cough drops recalled, imports blocked.

    High risk
  13. RC Outsourcing, LLC

    FDA warned outsourcing facility RC Outsourcing of Lowellville, Ohio, that its sterile drugs were made under insanitary conditions that risk contamination.

    High risk
  14. Apollo Care, LLC

    FDA cited Apollo Care for insanitary conditions and quality failures in sterile compounded drugs, including a sterility-assurance recall.

    High risk
  15. Medical Products Laboratories, Inc.

    Medical Products Laboratories was cited for manufacturing failures and selling unapproved prescription skin drugs.

    High risk
  16. Chemco Corporation

    FDA warns Chemco Corporation about CGMP failures and unapproved, misbranded OTC drug products from its Miami Lakes facility.

    High risk
  17. Purolea Cosmetics Lab

    Purolea Cosmetics Lab drug products were adulterated by insanitary conditions and manufacturing failures, and two Dermveda products are unapproved new drugs.

    High risk
  18. Schlechter Farms Inc.

    FDA found bird feces throughout Schlechter Farms' Oregon onion packing shed, adulterating onions and repeating 2023 violations.

    High risk
  19. Half Hill Farm Inc.

    FDA cited Half Hill Farm's mushroom extracts as unapproved new drugs over website disease-treatment claims.

    Low
  20. Ocean Group Inc.

    FDA found Listeria monocytogenes and seafood HACCP sanitation violations at Ocean Group's ready-to-eat salmon and tuna facilities.

    High risk
  21. Barcelona Nut Company Inc.

    Barcelona Nut Company in Baltimore found rodent and insect contamination and allergen cross-contact in ready-to-eat nuts and seeds.

    High risk
  22. Guangzhou Huli Technology Co., Ltd. dba Fantasy Face

    FDA warned Guangzhou Huli Technology (dba Fantasy Face) for selling an unapproved GLP-1 weight loss drug online.

    Medium
  23. Henan Lvyuan Pharmaceutical Co. Ltd.

    FDA warns Henan Lvyuan Pharmaceutical over CGMP failures at its API plant, including water leaks and incomplete batch records.

    High risk
  24. IsoTis OrthoBiologics, Inc.

    IsoTis OrthoBiologics in Irvine, CA failed to properly fix and assess possible particulate contamination in its Accell bone filler devices, FDA says.

    High risk
  25. Patcos Cosmetics Pvt. Ltd.

    Patcos Cosmetics, an Indian OTC drug manufacturer, was cited for insanitary conditions and CGMP violations after a 2025 FDA inspection.

    High risk
  26. OraLabs, Inc.

    FDA warned OraLabs, an OTC drugmaker in Parker, Colorado, that it skipped microbial release testing and dismissed contamination findings.

    High risk
  27. Flowchem Pharma Private Limited

    FDA warned India's Flowchem Pharma over dirty API equipment, exposed materials and untested impurities, and blocked its drug imports.

    High risk
  28. Vedic Lifesciences Pvt. Ltd.

    FDA warns Vedic Lifesciences over false final reports for three nonclinical drug studies.

    Medium
  29. JZ Wholesale, Inc.

    FDA warned JZ Wholesale after finding widespread rodent and insect contamination in food at its Fort Smith, Arkansas warehouse.

    High risk
  30. A TO Z Distributor Inc

    FDA warns Brooklyn food importer A TO Z Distributor for having no foreign supplier verification program for any imported food.

    Medium
  31. Apothecary Pharma, LLC

    FDA warns Apothecary Pharma, an outsourcing facility, that its sterile compounded drugs were made under insanitary conditions.

    High risk
  32. Simtra BioPharma Solutions

    FDA found contamination risks in Simtra's sterile drug manufacturing in Germany, including microbial recoveries, failed isolator tests, and inadequate decontamination.

    High risk
  33. Fareva Morton Grove

    FDA found microbial contamination risks and data integrity failures at Fareva Morton Grove's OTC drug manufacturing.

    High risk
  34. NSE Products, Inc. DBA Nu Skin Enterprises, Inc.

    FDA warns NSE Products (Nu Skin) over incomplete drug listing data for AP-24 products and 61 inactivated listings.

    Low
  35. Raw Bistro Inc.

    FDA warns Raw Bistro that its raw dog food contained Salmonella Paratyphi and its pathogen controls were inadequate.

    High risk
  36. Premium Health Management Inc. dba Premium Health

    FDA warns Premium Health over misleading website claims for compounded semaglutide and tirzepatide.

    Low
  37. Zeuss LLC dba Zeuss

    FDA warned telehealth seller Zeuss that its website misbrands compounded tirzepatide by implying Zeuss makes it and that it is FDA-approved.

    Medium
  38. Lean Rx, Inc. dba SkinnyRx

    SkinnyRx's website misbranded compounded semaglutide and tirzepatide by wrongly suggesting it makes the drugs and that they are FDA-approved.

    Low
  39. Kare Solutions, LLC dba Zappy

    FDA warned Zappy that its website falsely suggested it compounds semaglutide, tirzepatide, and liraglutide and made misleading approval-like claims.

    Low
  40. Strut Health, LLC dba Strut

    FDA says Strut Health's website falsely labeled compounded semaglutide and tirzepatide as its own and FDA-approved.

    Low
  41. Weightless Medical LLC dba WeightCare

    FDA warned telehealth seller WeightCare that its website falsely presents it as the compounder of semaglutide and tirzepatide drugs.

    Low
  42. Viv Health, Inc. dba VIV RX

    FDA warned telehealth company VIV RX that its website falsely suggests it compounds semaglutide and tirzepatide, making the drugs misbranded.

    Medium
  43. PharmaZee

    FDA warns PharmaZee over misleading website claims for compounded semaglutide and tirzepatide, including implying PharmaZee compounds them and that they are proven.

    Low
  44. Good Girl LLC dba GoodGirlRX

    FDA warns telehealth seller GoodGirlRX that its website misbrands compounded semaglutide and tirzepatide, claiming FDA approval and implying it is the compounder.

    Medium
  45. Ivim Services LLC dba Ivim

    FDA says Ivim's telehealth website mislabels compounded semaglutide and tirzepatide as Ivim-made when it is not the compounder.

    Low
  46. Join Josie

    FDA says Join Josie's website misbranded compounded semaglutide and tirzepatide by falsely implying FDA approval and naming Join Josie as compounder.

    Low
  47. Kin Meds

    FDA warned Kin Meds over false claims for compounded semaglutide and tirzepatide, including implying it is the compounder and that products are approved.

    Low
  48. Levity Inc. dba Levity

    FDA warned Levity over misleading website claims for compounded semaglutide and liraglutide, including implying Levity made the drugs and that they were FDA-approved.

    Low
  49. Better Health Labs, Inc. dba Measured

    FDA warned telehealth seller Measured its website misbranded compounded semaglutide and tirzepatide by implying it made them and that they were FDA-approved.

    Medium
  50. Newman Clinic, PLLC dba Newman Clinic

    FDA told Newman Clinic its website misbranded compounded semaglutide and tirzepatide with false and misleading claims.

    Medium